Monitor for upcoming partnership or financing announcements, as the Phase 2b DKD trial is contingent on external funding. The improved cash efficiency and strong clinical data may support near-term deal speculation, but lack of revenue and continued reliance on capital raises limit upside without a catalyst.
Price Chart
Executive Summary
Vivoryon Therapeutics reported full-year 2025 financial results with no revenue, reduced R&D and G&A expenses, and a narrowed net loss of EUR 8.9 million (vs. EUR 20.6M in 2024). Cash reserves stand at EUR 5.6 million, sufficient to fund operations into Q4 2026. The company highlighted positive kidney function data from Phase 2 studies of varoglutamstat and secured a U.S. patent extending exclusivity to 2044, but future clinical development remains contingent on securing additional funding or a partnership.
Key Financial Metrics
Key Facts
- No revenue generated in 2025
- Net loss narrowed to EUR 8.9 million in 2025 from EUR 20.6 million in 2024
- Cash and cash equivalents: EUR 5.6 million as of Dec 31, 2025 (down from EUR 9.4 million)
- Financial runway extended to Q4 2026 based on current plan
- Phase 2b DKD study initiation dependent on additional funding or partnership
- U.S. patent granted for varoglutamstat with exclusivity through 2044, potentially extendable to 2049
Financial Impact
Reduced cash burn from EUR 19.2M in 2024 to EUR 8.5M in 2025; cash runway now into Q4 2026
Risk Factors
- Clinical development delayed or halted without additional funding
- Dilution risk from potential future equity raises or SEPA utilization
- No revenue or near-term commercial path, increasing dependence on partnerships
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3279553 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | Press Release | — | awaiting T+20 | — | — |
Jul 22, 2026 13w ago | Press Release | — | awaiting T+20 | — | — |
Jun 11, 2026 19w ago | Press Release | — | awaiting T+20 | — | — |
Jun 8, 2026 20w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 15, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 9, 2026 28w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers